Literature DB >> 20207839

Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.

Martin Jädersten.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20207839      PMCID： PMC2833060          DOI： 10.3324/haematol.2009.019141

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  22 in total

1.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

2.  Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes.

Authors:  J-J Kiladjian; E Bourgeois; I Lobe; T Braun; G Visentin; J-H Bourhis; P Fenaux; S Chouaib; A Caignard
Journal:  Leukemia       Date:  2006-03       Impact factor: 11.528

Review 3.  Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.

Authors:  B L Ebert
Journal:  Leukemia       Date:  2009-03-26       Impact factor: 11.528

4.  Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Authors:  Daniel T Starczynowski; Florian Kuchenbauer; Bob Argiropoulos; Sandy Sung; Ryan Morin; Andrew Muranyi; Martin Hirst; Donna Hogge; Marco Marra; Richard A Wells; Rena Buckstein; Wan Lam; R Keith Humphries; Aly Karsan
Journal:  Nat Med       Date:  2009-11-08       Impact factor: 53.440

5.  Targeted therapies in myelodysplastic syndrome.

Authors:  Magda Melchert; Alan List
Journal:  Semin Hematol       Date:  2008-01       Impact factor: 3.851

6.  Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.

Authors:  Gudrun Göhring; Aristoteles Giagounidis; Guntram Büsche; Hans Heinrich Kreipe; Martin Zimmermann; Eva Hellström-Lindberg; Carlo Aul; Brigitte Schlegelberger
Journal:  Ann Hematol       Date:  2009-10-24       Impact factor: 3.673

7.  A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.

Authors:  Sheng Wei; Xianghong Chen; Kathy Rocha; P K Epling-Burnette; Julie Y Djeu; Qing Liu; John Byrd; Lubomir Sokol; Nick Lawrence; Roberta Pireddu; Gordon Dewald; Ann Williams; Jaroslaw Maciejewski; Alan List
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-26       Impact factor: 11.205

8.  Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.

Authors:  Martin Jädersten; Leonie Saft; Andrea Pellagatti; Gudrun Göhring; James S Wainscoat; Jacqueline Boultwood; Anna Porwit; Brigitte Schlegelberger; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2009-10-01       Impact factor: 9.941

9.  A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.

Authors:  Jillian L Barlow; Lesley F Drynan; Duncan R Hewett; Luke R Holmes; Silvia Lorenzo-Abalde; Alison L Lane; Helen E Jolin; Richard Pannell; Angela J Middleton; See Heng Wong; Alan J Warren; James S Wainscoat; Jacqueline Boultwood; Andrew N J McKenzie
Journal:  Nat Med       Date:  2009-11-22       Impact factor: 53.440

10.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.

Authors:  Benjamin L Ebert; Jennifer Pretz; Jocelyn Bosco; Cindy Y Chang; Pablo Tamayo; Naomi Galili; Azra Raza; David E Root; Eyal Attar; Steven R Ellis; Todd R Golub
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962
View more
  5 in total

1.  L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.

Authors:  Elspeth M Payne; Maria Virgilio; Anupama Narla; Hong Sun; Michelle Levine; Barry H Paw; Nancy Berliner; A Thomas Look; Benjamin L Ebert; Arati Khanna-Gupta
Journal:  Blood       Date:  2012-06-25       Impact factor: 22.113

Review 2.  A primary care approach to myelodysplastic syndromes.

Authors:  Djamshed Samiev; Vijaya R Bhatt; Joel D Armitage; Lori J Maness; Mojtaba Akhtari
Journal:  Korean J Fam Med       Date:  2014-05-22

3.  NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.

Authors:  D M Murphy; R Bejar; K Stevenson; D Neuberg; Y Shi; C Cubrich; K Richardson; P Eastlake; G Garcia-Manero; H Kantarjian; B L Ebert; G Mike Makrigiorgos
Journal:  Leukemia       Date:  2013-05-27       Impact factor: 11.528

4.  Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.

Authors:  Ota Fuchs
Journal:  Leuk Res Treatment       Date:  2012-02-13

Review 5.  Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.

Authors:  Aristoteles Giagounidis; Ghulam J Mufti; Pierre Fenaux; Ulrich Germing; Alan List; Kyle J MacBeth
Journal:  Ann Hematol       Date:  2013-09-10       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.